BACKGROUND: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer. METHODS: Seventeen chemotherapy-naive patients with advanced or recurred pancreatic cancer were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks. RESULTS: The median age of patients was 55 years (range 44-82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1 year survival rate was 18% in all 17 patients. Grade 3-4 toxic side effect was leucopenia only (29%) and was easily managed without infection. CONCLUSION: Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer.
BACKGROUND: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer. METHODS: Seventeen chemotherapy-naive patients with advanced or recurred pancreatic cancer were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks. RESULTS: The median age of patients was 55 years (range 44-82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1 year survival rate was 18% in all 17 patients. Grade 3-4 toxic side effect was leucopenia only (29%) and was easily managed without infection. CONCLUSION:Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: M L Rothenberg; M J Moore; M C Cripps; J S Andersen; R K Portenoy; H A Burris; M R Green; P G Tarassoff; T D Brown; E S Casper; A M Storniolo; D D Von Hoff Journal: Ann Oncol Date: 1996-04 Impact factor: 32.976
Authors: E S Casper; M R Green; D P Kelsen; R T Heelan; T D Brown; C D Flombaum; B Trochanowski; P G Tarassoff Journal: Invest New Drugs Date: 1994 Impact factor: 3.850
Authors: D P Kelsen; R K Portenoy; H T Thaler; D Niedzwiecki; S D Passik; Y Tao; W Banks; M F Brennan; K M Foley Journal: J Clin Oncol Date: 1995-03 Impact factor: 44.544
Authors: Orla Coleman; Michael Henry; Fiona O'Neill; Sandra Roche; Niall Swan; Lorraine Boyle; Jean Murphy; Justine Meiller; Neil T Conlon; Justin Geoghegan; Kevin C Conlon; Vincent Lynch; Ninfa L Straubinger; Robert M Straubinger; Gerard McVey; Michael Moriarty; Paula Meleady; Martin Clynes Journal: Proteomes Date: 2018-11-06